ADMIT Expert board
Members of the Aerosol Drug Management Improvement Team (ADMIT). Click the link for more information about the member.
Graham K Crompton
Edinburgh, UK
Why I am part of ADMIT?
What I try to achieve with ADMIT?
"It is a tragedy that, through no fault of their own, many patients are unable to obtain full benefit from inhalers as they cannot them correctly.
The first paper I published pointing out that many patient cannot use a pressurised metered dose inhaler was in 1976. This message was repeated in many of my subsequent publications but was completely unheeded. A quarter of a century after my first paper I could see no improvement in the number of patients able to use inhalers correctly. Following retirement from UK National Health Service I was therefore delighted to be asked to chair ADMIT as this allowed me to continue in my quest to improve inhalation therapy for millions of patients with airways disease not able to obtain full benefit from their prescribed therapy because of their inability to use inhalers correctly."
Peter J Barnes
National Heart and Lung Institute, Imperial College London, UK
Why I am part of ADMIT?
What I try to achieve with ADMIT?
"Inhalation therapy is critical for delivery of the most effective drugs in asthma and COPD but the techniques of inhaler therapy are often ignored in management. ADMIT aims to focus attention of inhalation devices and ensure that inhaled drugs are delivered more effectively in order to give a better therapeutic outcome."
Mariëlle E.A.C. Broeders
University Medical Centre Nijmegen, The Netherlands
Christopher J Corrigan
Department of Asthma, Allergy and Respiratory Science, Guy's, Kings's and St. Thomas' School of Medicine, London, UK
Why I am part of ADMIT?
What I try to achieve with ADMIT?
"I am part of ADMIT because, as a medical professional who treats patients with severe obstructive airways diseases, particularly asthma and COPD, I am aware of the fundamental importance of the correct delivery of inhaled drugs to the airways if they are to be effective. This simple but vital requirement transcends all guidelines but is barely mentioned in national or global “initiatives” for managing these diseases.
I hope through ADMIT to be able to bring this to the attention of the professional community so that a strategy for the appropriate prescription of inhaler devices which patients can use and want to use, and which deliver inhaled medication effectively and reliably is placed at the forefront of all management guidelines."
Lorenzo Corbetta
Università degli Studi di Firenze, Unità Funzionale di Medicina Respiratoria, Italy
Why I am part of ADMIT?
What I try to achieve with ADMIT?
"I’m proud to belong to ADMIT, a very useful initiative to improve the awareness of the importance of education in asthma, managed by a well-qualified but friendly board of experts, who work very hard to realize new and innovative solutions for the management of asthma.
To realize materials and researches in this important topic in order to convince health workers and patients on the importance of a correct treatment of asthma and correct technique of use of inhalers. I’d like to make available some of the ADMIT initiatives to the Italian community with translations and adaptations of the material produced by the ADMIT group."
Richard Dekhuijzen
University Medical Centre Nijmegen, The Netherlands
Jean-Christophe Dubus
Unité de Medicine Infantile, Marseille, France
Thomas Hausen
GP in office, Essen, Germany
Why I am part of ADMIT?
What I try to achieve with ADMIT?
"Two reasons enhanced my participation to ADMIT: first referring to the patients: I wish to raise interest for their illness, to improve understanding and acceptance of their illness, to raise the understanding of the necessity of the therapy, to improve the handling of therapy, in particular the correct inhalation and to improve compliance by better understanding the need for therapy.
Second reason is referring to the doctors, in particular to GP´s but pneumologists too, I wish to support them by the choice of the correct device, to choose the best substance, to inform and find out correct inhalation technique for better education of the patients."
Meinhard Paul Kneußl
Wilhelminenspital, Vienna, Austria
Federico Lavorini
Università degli Studi di Firenze Unità Funzionale di Medicina Respiratoria, Italy
Why I am part of ADMIT?
What I try to achieve with ADMIT?
"Choice of the right inhaler and correct inhalation technique are just as important as choosing the most effective medication in asthma and COPD patients. I hope through ADMIT to increase interest and scientific knowledge among doctors and patients in this aspect of asthma and COPD treatment."
M L Levy
University of Edinburgh, Division of Community Health Sciences: GP Section, UK
Soren Erik Pedersen
Department of Paediatrics, Kolding Hospital, Kolding, Denmark
Why I am part of ADMIT?
What I try to achieve with ADMIT?
"Since I wrote my MD thesis "Inhaler Use in Children with Asthma" I have had a great interest in inhaled therapy in children with asthma and the challenges associated the teaching children correct inhaler use. I want the level of asthma control in children to be improved. To achieve this better knowledge among health care providers and patients about correct inhaler use and choice in various age groups of children is critical. "
Antonio Ramalho de Almeida
Hospital Ordem da Trindade, Porto, Portugal
Why I am part of ADMIT?
What I try to achieve with ADMIT?
"ADMIT has the challenge to work on the improvement of inhalation in asthma and COPD. I am happy to be part of this great ADMIT team and I hope that we can support the health care community and so improve the treatment of asthma and COPD."
Joaquin Sanchis
Departament de Pneumologia, Hospital de la Santa Creuide Sant Pau, Universitat Autónoma de Barcelona, Spain
Why I am part of ADMIT?
What I try to achieve with ADMIT?
"Along the last 25 years the treatment of Asthma has been steadily improving to the point that we are now convinced that Asthma control is an attainable goal to reach. The clinical reality is, however, deceiving: too many patients bear up their asthma with frequent and troublesome symptoms. In a sizeable portion of these Asthma patients, the lack of control can be attributed to faulty aerosol inhalation technique. Both, patients and physicians, may be blamed for this failure.
The reason for me to join ADMIT is to collaborate in improving the use of medical aerosols and thus the treatment of Asthma and COPD, by optimising and disseminating the use of available drugs in these ailments."
José Luis Viejo
Hospital General Yagüe de Burgos, Spain
Why I am part of ADMIT?
What I try to achieve with ADMIT?
"Is the first European Working Team with the aim to obtain a correct use of inhaler therapy, with the objective to help to improve treatment of obstructive lung diseases. My propose is to achieve a better management and a better control of the Asthma and COPD."
Walter G Vincken
Academisch Ziekenhuis VUB, Dienst Pneumologie, Brussels, Belgium
Why I am part of ADMIT?
What I try to achieve with ADMIT?
"I joined the ADMIT group because I am convinced that apart from the inhaled drugs themselves, benefit from and adherence to inhalation therapy of asthma and COPD patients depend to at least equal extents on the choice and the correct handling of the inhaler devices.
With the ADMIT group I try to achieve enhanced interest among patients, doctors and their trainers in this much neglected aspect of asthma and COPD treatment."
Thomas H Voshaar
Krankenhaus Bethanien, Moers, Germany
Why I am part of ADMIT?
What I try to achieve with ADMIT?
"For many years I have a special interest in aerosol medicine. During my daily work as a hospital doctor in a specialized department of pneumology I am aware of the positive development of inhalation therapy treating asthma and COPD. But I also realize that there is still a lack of knowledge on both sides, patients and doctors. There is room for improvement in training doctors and patients, and also pharmaceutical companies.
ADMIT is a wonderful international platform to exchange experiences and scientific knowledge in order to find new ways to improve inhalation therapy worldwide."
